Integra LifeSciences Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
BTIG Downgrades Integra LifeSciences (IART) to Sell
July 29, 2024 4:10 PM EDTBTIG analyst Ryan Zimmerman downgraded Integra LifeSciences (NASDAQ: IART) from Neutral to Sell with a price target of $22.00.
The analyst comments "We are downgrading to SELL following 2Q24 results, setting a $22 PT at 8.5x our 12-24 month EPS estimate. Another quarter and another negative update regarding IART's manufacturing and quality controls pushing out recovery to FY26. At the same time, IART's 2Q24 results were not bad. IART reported rev. of $418.2M (9.7%, 2.3% organic, 0.3% organic ex. Boston) and adj. EPS... More
